RALOXIFENE INSTEAD OF NOLVADEX

[PHIL HERNON]

Anyone hear of this new drug?

 

[xcelbeyond]

No - but saw this recent post asking same thing http://www.professionalmuscle.com/forums/showthread.php?t=13048

 

[jotun]

Yes, it is slightly more effective than Nolvadex at keeping estrogen-related sides down on a cycle. Despite of this, many still feel that Nolvadex is better for PCT than Raloxifene and only use Raloxifene during the cycle.

 

[Rex Feral]

Very little evidence in the literature so far. What little there is seems to support anecdotal reports. If gyno is not an issue for you, due to either the fact that you are not prone or have had your glands removed surgically, I see no advantage in raloxifene vs. tamoxifen as of yet. Both are lipid friendly. From what I can see one is not significantly better than the other. If you are using tamox in an effort to treat existing gyno or you are particularly prone, then it appears that raloxifene is clearly the better choice.

1: J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

Comment in:

* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.
* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.

Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
Department of Pediatrics, University of Ottawa, Ontario, Canada.

[email protected]

OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifene in the medical management of persistent pubertal gynecomastia.

STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).

RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

PMID: 15238910 [PubMed - indexed for MEDLINE]

Rex.

 

[Fastandfurious]

Great drug !
although i'm far from the average person in terms of what works for me,what doesn't ,what gives me sides and what doesn't (tren only makes me cut and gives me no strength/i hate test/i love deca etc) it made significant changes to my mostly progesterone induced gyno (from tren and deca).Nolva in fact made it worse,evista made it significantly less in 10 days .I used it with letro,but i found it works even better with aromasin.
Although it's not medically used in breast cancer but only in osteoporosis in women,it works marvelously.Some say toremifen works even better (i'll use this next).
I say if you find it in good price,go for it.

 

[joshbarnett]

saw this on yahoo news

WASHINGTON - Women at high risk of breast cancer after menopause often shun a protective drug for fear of side effects. Now a striking study shows a widely used bone drug prevents breast cancer, too — a safer yet equally effective alternative to that old standby tamoxifen.

ADVERTISEMENT

At least 2 million women might benefit from raloxifene's cancer-reducing effects, researchers said Monday in announcing initial results of the $88 million government study.

"Now women have a choice," Dr. Leslie Ford, NCI's cancer prevention chief, said in an interview. "It's good news, because we're giving you a choice with fewer side effects."

Until now, the decades-old tamoxifen has been doctor's only choice to reduce the chances of breast cancer striking high-risk women.

Manufacturer Eli Lilly & Co. already sells raloxifene, under the brand name Evista, to combat bone-thinning osteoporosis, another disease common after menopause. Armed with the new study of nearly 20,000 women, Lilly now plans to seek Food and Drug Administration approval to market raloxifene as a cancer-preventer, too.

Both drugs are so-called "selective estrogen response modulators" — they act like the estrogen hormone in some tissues, but like an anti-estrogen in others. Estrogen can fuel certain breast cancers. But by acting like an estrogen in the uterus and bloodstream, tamoxifen causes some rare but serious side effects, increasing users' risk of getting uterine cancer or a life-threatening blood clot.

Raloxifene is a close chemical relative. The NCI study compared the two, and found that taking either tamoxifen or raloxifene daily for up to five years cut in half women's chances of developing invasive breast cancer.

Raloxifene causes the same side effects, but not as many: Raloxifene users had 36 percent fewer uterine cancers and 29 percent fewer blood clots, the NCI announced Monday. Raloxifene users also suffered fewer vision-blocking cataracts.

While the reduction in those side effects was significant, the study also shows how uncommon they are. Thirty-six tamoxifen users developed uterine cancers, compared with 23 raloxifene users. The risk of blood clots was similarly low: 54 tamoxifen users had one in the lung, compared with 35 raloxifene users.

Still, many candidates for tamoxifen risk-reduction therapy have long avoided it for fear of those side effects, noted Dr. Kathy Albain of Loyola University, a study researcher.

"Here we have something that's a little less scary," Albain said. "It might tip the scales for a lot of women."

The new study means no change for pre-menopausal women — there's no data showing whether raloxifene is safe for them, Albain stressed.

Nor does it mean that tamoxifen users should necessarily switch, she said. Women currently are prescribed tamoxifen for five years, and its breast cancer prevention benefit continues even after they stop taking the drug — as raloxifene's seems to. So a woman already in, say, year 4 of her tamoxifen course with no sign of side effects probably has little to gain by switching, she explained.

But that's a question researchers were girding for as they spent Monday notifying study participants of the results.

One puzzle: While raloxifene was equally effective in blocking invasive breast cancer, it didn't protect quite as well as tamoxifen against noninvasive types of breast cancer such as ductal carcinoma in situ, noted Dr. Len Lichtenfeld of the American Cancer Society.

That type of tumor isn't life-threatening and shouldn't water down the overall message of raloxifene's benefit, said Dr. Victor Vogel of the University of Pittsburgh, who oversaw the study's design.

Among postmenopausal women, who's at high risk? Most of the study participants had a 4 percent chance of getting breast cancer within five years — because of advanced age, a close relative with the disease, never having a child or having one late in life, or other well-known risk factors that women can calculate on a government Web site: http://cancer.gov/bcrisktool.

In simpler terms, for every 1,000 of those women, doctors expected 40 to develop breast cancer within five years if they did nothing, but taking one of the drugs cut that number to 20, Ford explained.

 

[edge250]

it was on the national news last night, they were talking about how much more effective it is and it compared to tamoxifen/nolva

 

[w8tlifterty]

Hey Phil,
I love the stuff, used 120mg a day for 3 weeks and it knocked out some stubborn gyno i had that nolva did nothing for, it works very well for me. No side effects to speak of, I now am using 40mg a day to keep gyno at bay. I have heard though that nolva is far better for pct. I've tried to research it, but it's relatively new so there isn't much out there on it. Anyway thats just my personel experience

 

[simon birch]

Sounds good to me!

This looks like it's gonna be a nice new addition to my next cycle.

 

[healthfreak79]

I saw something about that drug on the news, and the guy was saying how it has a lot less side effects of nolva. So of the stuff he was saying about nolva was bad. They both have side effects, and they both have the same side effects for the most part is just that the nolva is worse. Sorry if i cant explain it that good you had to watch the show a lot of doctor talk..LOL

Edge 250 i saw that same new program

 

[VNV]

Do any research chemical sites offer raloxifene, or would one have to look at the powder sources for this?

 

[w8tlifterty]

One of our sponsers, CHEMONE offers it...There are several others out there with it on there list....